Official Opening of Winsford Facility
For Release: 27 January 2011
Advanced Medical Solutions Group plc
(“AMS” or the “Company”)
Official opening of Winsford facility
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces the official opening of its new world-class facility in Winsford, Cheshire. This marks a significant milestone in the development of the business and also celebrates 20 years from the founding of the Company.
The 138,500 sq ft facility incorporates offices, laboratories and warehouse space, as well as new state of the art manufacturing lines, which represent a major upgrade of the operational capability of AMS’s advanced woundcare business.
Dr. Don Evans, Chairman of AMS, stated: “We began this major project in 2008 and I am delighted to confirm that the new facility has been completed on time and on budget. Together with our wound closure operation in Plymouth and our foam facility in the Netherlands, AMS is now well positioned to support substantial growth and we look forward to the next stage of AMS’s development with confidence.”
– ends –
For further enquiries:
Advanced Medical Solutions Group plc +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer
Mary Tavener, Finance Director
Tavistock Communications +44 (0) 20 7920 3150
John West / Chris Munden / Andrew Dunn / Lydia Eades
Investec Bank plc +44 (0) 20 7597 5970
Gary Clarence / Patrick Robb / Daniel Adams
Notes to Editors:
AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.
AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.
AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.
This information is provided by RNS